---
title: "EAST-ASIA PHARMACEUTICAL released its first-quarter performance, reporting a net loss attributable to the parent company of 6.9196 million yuan, turning from profit to loss"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/238015011.md"
description: "According to the Zhitong Finance APP, EAST-ASIA PHARMACEUTICAL released its first-quarter report for 2025. The company's first-quarter operating revenue was 191 million yuan, a year-on-year decrease of 45.85%; the net loss attributable to shareholders of the listed company was 6.9196 million yuan, turning from profit to loss; the net loss attributable to shareholders of the listed company, excluding non-recurring gains and losses, was 10.5059 million yuan, turning from profit to loss; the basic loss per share was 0.06 yuan/share"
datetime: "2025-04-29T09:08:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/238015011.md)
  - [en](https://longbridge.com/en/news/238015011.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/238015011.md)
---

# EAST-ASIA PHARMACEUTICAL released its first-quarter performance, reporting a net loss attributable to the parent company of 6.9196 million yuan, turning from profit to loss

According to the Zhitong Finance APP, EAST-ASIA PHARMACEUTICAL (605177.SH) released its first-quarter report for 2025. The company's first-quarter operating revenue was 191 million yuan, a year-on-year decrease of 45.85%; the net loss attributable to shareholders of the listed company was 6.9196 million yuan, turning from profit to loss; the net loss attributable to shareholders of the listed company after deducting non-recurring gains and losses was 10.5059 million yuan, turning from profit to loss; the basic loss per share was 0.06 yuan/share

### Related Stocks

- [605177.CN](https://longbridge.com/en/quote/605177.CN.md)

## Related News & Research

- [Should You Be Adding Daewoong Pharmaceutical (KRX:069620) To Your Watchlist Today?](https://longbridge.com/en/news/286824214.md)
- [China's Bio-Thera Gets US Nod for Golimumab Biosimilar](https://longbridge.com/en/news/286880573.md)
- [While Everyone Chases AI, Pharma Keeps Getting Cheaper](https://longbridge.com/en/news/286650835.md)
- [Rare nickels that could fund your dreams](https://longbridge.com/en/news/286856785.md)
- [Claritas Rx Strengthens Executive Team with New CRO and Two VP Promotions](https://longbridge.com/en/news/286794376.md)